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BACKGROUND Use of mechanical circulatory support (MCS) devices
in cardiogenic shock (CS), acute Myocardial Infarction (MI), high-risk
percutaneous coronary interventions (PCI) has been extensively
studied. High-risk surgical patients with valvular heart diseases un-
dergoing percutaneous treatment such as transcatheter aortic valve
replacement (TAVR) represent an emerging population which may
beneﬁt from short term use of MCS.
METHODS We analyzed data from Nationwide Inpatient Sample (2011
and 2012) using the ICD, 9th Revision, Clinical Modiﬁcation procedure
codes.
RESULTS A total of 1,794 TAVR procedures (375 hospitals in the US)
were identiﬁed of which 190 (10.6 %) utilized a MCS device (MCS
group) and 1,604 (89.4%) did not (non-MCS group). A higher per-
centage of patients in MCS group underwent trans-apical TAVR (54%
vs 13%, p<0.01), had AMI (6.4% vs. 2.1%, p<0.01), underwent percu-
taneous coronary intervention (5.4% vs. 2.1%, p<0.01), had cardiac
arrest (10% vs. 2.3%, p¼<0.01) (including ventricular ﬁbrillation: 8%
vs. 1%, p¼<0.01) and cardiogenic shock (16.8% vs. 2.9%, p<0.01)
when compared to the non-MCS group. On the other hand the patients
in non-MCS group were older (71% vs. 37% >80 years old, p<0.01) and
had a higher mean Charlson’s comorbidity score (2.650.04 vs. 20.1,
p<0.01).The use of MCS devices with TAVR was associated with sig-
niﬁcant increase in the in-hospital mortality (14.9% vs. 3.5%, p<0.01).
The mean length (11.80.8 vs. 8.10.2 days, p<0.01) and cost
($68,9973,656 vs. $55,878653, p¼0.03) of hospitalization were also
signiﬁcantly higher in MCS group. Ventricular ﬁbrillation arrest, trans-
apical access for TAVR and cardiogenic shock, were the most signiﬁ-
cant predictors of MCS use during TAVR. In the multivariate model,
use of any MCS device was found to be an independent predictor of
increased mortality (OR 3.5, 95% CI 2.6-4.6, p<0.0001) and compli-
cations (OR 3.3, 95% CI 2.8-3.9, p<0.0001) Figure 1. The propensity
score matched analysis (n¼160 in each group) also showed a similar
result.CONCLUSIONS The unacceptably high rates of mortality and com-
plications coupled with a signiﬁcant increase in the length and cost of
hospitalization should raise concerns about utility of MCS devices
during TAVR in this prohibitive surgical risk population.
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BACKGROUND Intra-aortic balloon pump (IABP) is the most
commonly utilized mechanical support device in the cardiac cathe-
terization laboratories. The last decade has witnessed the develop-
ment and Food and Drug Administration approval of alternative
percutaneous ventricular assist devices (PVADs) such as Impella
(Abiomed, Danvers, MA, USA) and TandemHeart (Cardiac Assist, Inc.,
Pittsburgh, PA). Despite the lack of clear evidence of superiority, the
utilization of PVAD has increased substantially in the last decade. The
present study was designed to provide further insights into PCIs
performed with hemodynamic support (IABP or PVAD) using the na-
tion’s largest available hospitalization database.
METHODS This was a cross sectional study using the Nationwide
Inpatient Sample database between the years 2008-2012. Procedures
were identiﬁed through appropriate clinical modiﬁcation of Interna-
tional Classiﬁcation of Diseases, ninth edition (ICD-9-CM) codes for
PCI, PVAD and IABP placement. We used propensity-scoring method
to establish matched cohorts in order to control for imbalances of
patients’ and hospitals’ characteristics between the studied groups
which may have inﬂuenced the primary outcome.
RESULTS A total of 18,094 procedures were identiﬁed over the ﬁve
year study period between 2008 through 2012. IABP was the most
commonly utilized hemodynamic support device (93%, n¼16, 803)
whereas 6% (n¼1069) were performed with PVADs and 1% (n¼222)
utilized both IABP and PVAD. Patients in the PVAD group were older
in age and had greater burden of co-morbidities when compared to
those in the IABP group. A higher proportion of patients in the PVAD
group were admitted emergently whereas IABP group had higher
percentage of patients with cardiac arrest. We observed an in-hospital
mortality rate of 20.1% for IABP, 12% with PVAD and 41% in IABP+P-
VAD group. Overall complications rate for this patient population was
36% for IABP vs. 26% for PVAD vs. 52% for the IABP+PVAD group. The
use of PVADs was a signiﬁcant predictor of reduced mortality (OR
0.16, 0.07-0.36, p<0.0001, as well as complications rate (OR 0.45,
0.32-0.64, p<0.001) when compared to IABP only in the sub-group of
patients without AMI or cardiogenic shock. Propensity score matched
analysis also showed a signiﬁcantly lower mortality (9.9% vs. 15.1%;
OR 0.62, 0.55-0.71, p<0.001) and complications (24.8% vs. 31.5%; OR
